Correlation Between TC BioPharm and Cell Source

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both TC BioPharm and Cell Source at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining TC BioPharm and Cell Source into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between TC BioPharm plc and Cell Source, you can compare the effects of market volatilities on TC BioPharm and Cell Source and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in TC BioPharm with a short position of Cell Source. Check out your portfolio center. Please also check ongoing floating volatility patterns of TC BioPharm and Cell Source.

Diversification Opportunities for TC BioPharm and Cell Source

-0.69
  Correlation Coefficient

Excellent diversification

The 3 months correlation between TCBPW and Cell is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding TC BioPharm plc and Cell Source in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cell Source and TC BioPharm is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on TC BioPharm plc are associated (or correlated) with Cell Source. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cell Source has no effect on the direction of TC BioPharm i.e., TC BioPharm and Cell Source go up and down completely randomly.

Pair Corralation between TC BioPharm and Cell Source

Assuming the 90 days horizon TC BioPharm plc is expected to generate 1.56 times more return on investment than Cell Source. However, TC BioPharm is 1.56 times more volatile than Cell Source. It trades about 0.14 of its potential returns per unit of risk. Cell Source is currently generating about 0.1 per unit of risk. If you would invest  1.25  in TC BioPharm plc on September 23, 2024 and sell it today you would earn a total of  0.26  from holding TC BioPharm plc or generate 20.8% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy83.46%
ValuesDaily Returns

TC BioPharm plc  vs.  Cell Source

 Performance 
       Timeline  
TC BioPharm plc 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in TC BioPharm plc are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, TC BioPharm showed solid returns over the last few months and may actually be approaching a breakup point.
Cell Source 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cell Source are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental indicators, Cell Source unveiled solid returns over the last few months and may actually be approaching a breakup point.

TC BioPharm and Cell Source Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with TC BioPharm and Cell Source

The main advantage of trading using opposite TC BioPharm and Cell Source positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if TC BioPharm position performs unexpectedly, Cell Source can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cell Source will offset losses from the drop in Cell Source's long position.
The idea behind TC BioPharm plc and Cell Source pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets